The expression and clinical significance of SHP-1 and JAK1 mRNA in patients with acute leukemia
10.3760/cma.j.issn.1009-9921.2008.04.008
- VernacularTitle:急性白血病患者SHP-1与JAK1 mRNA的表达与临床意义
- Author:
Yinghua LI
;
Jianmin LUO
;
Xingyan DU
- Publication Type:Journal Article
- Keywords:
Leukemia,acute;
SHP-1 protein tyrosine phosphatase;
Janus kinase 1;
RTPCR;
Anti-oncogene
- From:
Journal of Leukemia & Lymphoma
2008;17(4):264-266,270
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of SHP-1 and JAK1 mRNA in acute leukemia patients and their impact on disease development,and outcome of the primary chemotherapy.Methods Semi-quantitative reverse transcription polymerase chain reaction was used to measure the expression of SHP-1 and Janus kinase 1(JAK1)mRNA in 93 patients with acute leukemia(AL)and 20 healthy adults as normal 、controls(NC).Results The expression of SHP-1 mRNA in de novo AL patients was significantly lower than that in NC group(P=0.000),which was elevated when complete remission(CR)was achieved(P=0.032)and decreased after the disease relapsed (P=0.015).The expression of JAK1 mRNA in NC group was a lower than that in de novo AL group, but with no statistical significance(P=o.051).While there was statistical significance between NC group and relapsed AL group(P=0.047).The complete remission(CR)rate of the primary chemotherapy in SHP-1 positive group Was 88.9%,but 60.38%in negative group,and there was a statistical significance between them(P=0.018).There Was a negative correlation between the expression level of SHP-1 and JAKI mRNA (P=0.048).Conclusion The expression of SHP-1 mRNA Was significantly decreased or absent in the specimens of acute leukemia patients,and the positive expression of SHP-1 mRNA may be proposed as a factor of preferable therapeutic efficacy in de novo AL and a marker for the progress of the disease.The abundance of JAK1 mRNA was possibly elevated in patients with acute leukemia.
